Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,559,080
  • Shares Outstanding, K 59,318
  • Annual Sales, $ 305,440 K
  • Annual Income, $ 34,600 K
  • 60-Month Beta 0.58
  • Price/Sales 11.61
  • Price/Cash Flow 24.34
  • Price/Book 10.31
Trade HRMY with:

Options Overview Details

View History
  • Implied Volatility 64.64% ( +1.20%)
  • Historical Volatility 48.14%
  • IV Percentile 37%
  • IV Rank 51.26%
  • IV High 126.01% on 01/19/22
  • IV Low 0.11% on 02/16/22
  • Put/Call Vol Ratio 0.06
  • Today's Volume 17
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 2.28
  • Today's Open Interest 834
  • Open Int (30-Day) 814

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.54
  • Number of Estimates 4
  • High Estimate 0.57
  • Low Estimate 0.50
  • Prior Year 0.63
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.06 +14.13%
on 11/17/22
61.55 -1.61%
on 11/15/22
+2.07 (+3.54%)
since 11/02/22
3-Month
41.83 +44.78%
on 09/26/22
61.55 -1.61%
on 11/15/22
+16.20 (+36.52%)
since 09/02/22
52-Week
31.54 +92.02%
on 01/24/22
61.55 -1.61%
on 11/15/22
+23.73 (+64.43%)
since 12/02/21

Most Recent Stories

More News
Why Harmony Biosciences (HRMY) Stock Might be a Great Pick

Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

HRMY : 60.40 (+0.67%)
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...

HRMY : 60.40 (+0.67%)
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2022.

HRMY : 60.40 (+0.67%)
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

HRMY : 60.40 (+0.67%)
ARCT : 19.10 (+3.86%)
HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

HRMY : 60.40 (+0.67%)
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACAD : 15.83 (+3.19%)
HRMY : 60.40 (+0.67%)
Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRMY : 60.40 (+0.67%)
ALNY : 234.36 (+6.41%)
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and...

HRMY : 60.40 (+0.67%)
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

ALBO : 23.77 (+3.62%)
HRMY : 60.40 (+0.67%)
HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

HRMY : 60.40 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 61.60
2nd Resistance Point 61.00
1st Resistance Point 60.50
Last Price 60.40
1st Support Level 59.40
2nd Support Level 58.80
3rd Support Level 58.30

See More

52-Week High 61.55
Last Price 60.40
Fibonacci 61.8% 50.09
Fibonacci 50% 46.54
Fibonacci 38.2% 43.00
52-Week Low 31.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar